US-based cancer diagnostics technology developer Epic Sciences has closed a $40m series D round that featured genetic research company Genomic Health.
Private equity fund Hermed Capital led the round, while RMI Partners, which manages the Russian state-owned investment fund RusnanoMedInvest, Domain Associates, Pagoda Investment, Reach Tone, Sabby Capital and VI Ventures also contributed capital.
Epic Sciences is working on a range of blood-based tests that will be capable of predicting therapy response in cancer patients. Genomic Health’s financial commitment follows a partnership between the two to collaborate on the commercialisation of one such test.
The cash will be used to accelerate clinical studies and to enhance the company’s technology, dubbed No Cell Left Behind.
Epic Sciences raised $30m in a 2014 series C round backed by Roche Venture Fund and Pfizer Venture Investments, the respective corporate venturing vehicles for pharmaceutical firms Roche and Pfizer, as well as Domain, RMI, Arcus Ventures and unnamed private investors.
Roche Venture Fund, Pfizer Venture Investments and Domain had previously invested in Epic’s $13m series B round in 2012. Venrock supplied $2.5m in series A funding in 2009, according to an unsourced claim by deals database Crunchbase.